Back
Sarepta Therapeutics Vs. AbbVie Industry Stock Comparison
Sell
42
SRPT
Sarepta Therapeutics
Last Price:
$18.20
Seasonality Move:
17.08%
Buy
60
ABBV
AbbVie
Last Price:
$190.75
Seasonality Move:
3.46%
Sell
42
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
-
The current Sarepta Therapeutics [SRPT] share price is $17.71. The Score for SRPT is 42, which is 16% below its historic median score of 50, and infers higher risk than normal.
-
SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $17.71Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and SRPT is experiencing slight selling pressure.
SRPT Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -6.88 | Sell |
Relative Strength Index (14 RSI): | 20.93 | Sell |
Chaikin Money Flow: | -284712 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (20.01 - 39.83) | Sell |
Bollinger Bands (100): | (32.22 - 93.14) | Sell |
ABBV Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.23 | Sell |
Relative Strength Index (14 RSI): | 55.85 | Buy |
Chaikin Money Flow: | 3087554 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (184.54 - 189.82) | Buy |
Bollinger Bands (100): | (181.02 - 204.06) | Sell |
SRPT Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 18.07 | Sell |
20-day SMA: | 27.93 | Sell |
50-day SMA: | 39 | Sell |
200-day SMA: | 92.52 | Sell |
8-day EMA: | 19.21 | Sell |
20-day EMA: | 25.55 | Sell |
50-day EMA: | 38.74 | Sell |
200-day EMA: | 80.29 | Sell |
ABBV Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 185.59 | Buy |
20-day SMA: | 187.6 | Buy |
50-day SMA: | 186.41 | Buy |
200-day SMA: | 188.22 | Buy |
8-day EMA: | 186.5 | Buy |
20-day EMA: | 186.72 | Buy |
50-day EMA: | 187.49 | Buy |
200-day EMA: | 186.06 | Buy |
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.02 per share, an increase next quarter of $0.86 per share, a decrease this year of $5.90 per share, and an increase next year of $5.54 per share.
AbbVie Earnings Growth & ABBV Earnings Dates
-
Analysts estimate an earnings increase this quarter of $0.29 per share, a decrease next quarter of $1.88 per share, an increase this year of $2.07 per share, and an increase next year of $1.72 per share.
Sarepta Therapeutics Technical Analysis
Jun 17 | Jun 18 | Jun 20 | Jun 23 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 30 | Jul 1 | |
---|---|---|---|---|---|---|---|---|---|---|
Jun | ||||||||||
17 | 18 | 20 | 23 | 24 | 25 | 26 | 27 | 30 | 01 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
AbbVie Technical Analysis
Jun 17 | Jun 18 | Jun 20 | Jun 23 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 30 | Jul 1 | |
---|---|---|---|---|---|---|---|---|---|---|
Jun | ||||||||||
17 | 18 | 20 | 23 | 24 | 25 | 26 | 27 | 30 | 01 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |